Next-generation multiple myeloma treatment: a pharmacoeconomic perspective. - Wikidata - wikimedia - TriplyDB

Next-generation multiple myeloma treatment: a pharmacoeconomic perspective.

Next-generation multiple myeloma treatment: a pharmacoeconomic perspective.

http://www.wikidata.org/entity/Q38981247

about

Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation.Melphalan hydrochloride for the treatment of multiple myeloma.Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma.Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma.New drugs in myeloma: beware of phase I trial results, beware of cost and demand for new trials.Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents.Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

P2860

Q38605030-AF9782F2-BF92-4CC3-A6DF-88481235BF68 Q38704146-E6528E5E-8987-4065-8F92-B621891604AC Q38742055-50A2AF65-956F-438C-97C7-B2062CBD87CA Q38765324-E2B4ED16-0C9C-4B1F-9D30-31F5DC90274F Q47283493-3B49A783-2562-4B7F-8F1B-D0F49E2AAFBC Q47614728-7472A003-BE14-4A5E-84DE-F34E107DCD18 Q47784917-56DE20A2-13C2-497C-B23E-A80A68AC4283 Q53187875-07DAAEAF-EAFD-4CC2-9799-B22FAE9DC70C Q55119916-509A1051-A7BE-4FA5-9307-4E66622873E1 Q58560605-9D084C47-6CDC-40C4-BAD4-BBFFF3081158

P2860

Next-generation multiple myeloma treatment: a pharmacoeconomic perspective.

http://www.wikidata.org/entity/Q38981247

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Next-generation multiple myeloma treatment: a pharmacoeconomic perspective.

@en

type

label

Next-generation multiple myeloma treatment: a pharmacoeconomic perspective.

@en

prefLabel

Next-generation multiple myeloma treatment: a pharmacoeconomic perspective.

@en

P1433

Q38981247-05407DE7-E207-4E58-8540-AE42963EBCE0

P1476

Q38981247-6F69ED90-69A4-4FCD-AD0E-8F1EB69D9C75

P2093

Q38981247-09922E15-96D0-463B-9957-8B59929757DA

P2860

Q38981247-01467927-DAE3-4501-9DF6-BB2E72FE718C

Q38981247-02C408AC-0094-47A1-B8E0-4565DE252A96

Q38981247-03B8B03C-FEC3-4C92-8C2B-C7FCE8FAF579

Q38981247-0423D862-BEFC-48A1-BA11-2928F9B6395D

Q38981247-06988546-D17E-419E-BB5A-B7E74CFC79A6

Q38981247-0EC59BF4-F48F-4E0C-BD06-E78C10728055

Q38981247-1B20881A-62BC-4AF0-A8EF-0B0913F85BCE

Q38981247-2028AE91-C73E-4F5E-885D-CB29B4419F45

Q38981247-26A32FFE-B4DB-4E39-9F78-22FCF79D5B62

Q38981247-279B1E84-C0C5-4FED-BF35-1FED01554E36

P304

Q38981247-446C23A4-56EE-42C3-8C13-FA7CB09062D9

P31

Q38981247-C0488C50-6B4B-4B37-8514-FB8A748B81F8

P356

Q38981247-A8A4CC69-07E2-4378-A0F5-7C4ACBDFF485

P407

Q38981247-03339615-F438-425B-87EC-AD2F22B22AC4

P433

Q38981247-ECAD0B2C-A6AC-41D2-B51E-FE6424817552

P478

Q38981247-09BAF785-E052-4C73-8DBE-7D33FCF88A7F

P50

Q38981247-0C5A5699-7BED-4D8C-95CF-6A5021A37F72

P577

Q38981247-1BD1F5C5-C75B-48B3-AB80-3C2D38AA2FD6

P698

Q38981247-E1C3D351-871F-4C50-A72A-329C667344C9

P932

Q38981247-3D26307E-9044-4A05-AF9E-E054431C5C9E

P356

BLOOD-2016-09-692947

P1433

P1476

Next-generation multiple myeloma treatment: a pharmacoeconomic perspective.

@en

P2093

Jean Luc Harousseau

http://www.w3.org/2001/XMLSchema#string

P2860

Feasibility and attractiveness of indication value-based pricing in key EU countries

Interpretation of cytogenetic results in multiple myeloma for clinical practice

Bringing in health technology assessment and cost-effectiveness considerations at an early stage of drug development

New investigational drugs with single-agent activity in multiple myeloma

Chromosome translocations in multiple myeloma

The Value of Medicines: A Crucial but Vague Concept.

The Medical Imaging & Technology Alliance conference on research endpoints appropriate for Medicare coverage of new PET radiopharmaceuticals.

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

P304

2757-2764

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2016-09-692947

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

128

http://www.w3.org/2001/XMLSchema#string

P50

S. Vincent Rajkumar

P577

2016-10-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27742709

http://www.w3.org/2001/XMLSchema#string

P932

5159700

http://www.w3.org/2001/XMLSchema#string